Description ofchanges in that part of the nervous sstem that is proces
A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Dimethyl fumarate
Kelch-like ECH-associated protein 1 inhibitor
What it measured
Main measures
Parameters of interest
Other measures (1)
not applicable
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Written informed consent from patients capable of giving or withholding full informed consent must be obtained before any assessment is performed. Exclusion: 1. Patients that are unwilling or unable to comply with study requirements, or are deemed unsuitable for study participation as determined by the Investigator.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Evaluation of changes of the visual sysetm in RRMS patients treated with dimethyl fumarate assessed by RNFL thickness measured by OCT over 36 months
Loading reviews and guidelines…
Related trials
- A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dime
Phase 3 · Not yet recruiting
Still running
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
Recruiting
Still running
- Observational Study of Persistence on Bafiertam Treatment in Routine C
Stopped early
Stopped
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Scle
Phase 4 · Completed
No results found
- Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Di
Running, not recruiting
Still running
History
Started
Apr 2014